Biomarker ID | 25 |
PMID | 11489752 |
Year | 2001 |
Biomarker | Insulin Like Growth Factor-1 (IGF-1) |
Biomarker Basis | Concentration Based (ng/ml) |
Biomolecule | Protein |
Source | Plasma |
Subjects | Humans |
Regulation | Dowregulated (Preintervention: 232.7 ± 20.6 ng/mL Vs Postintervention: 16.92 ± 23.3 ng/mL) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Skeletal myogenesis control by HDAC and calcium/calmodulin-dependent kinase (CaMK),BAD phosphorylation regulation,Fibroblast growth factor 1,IGF1 signaling pathway,IGF1 receptor signaling through beta-arrestin |
Experiment | Prostate Cancer patients pre and post treatment with Lycopene |
Type of Biomarker | Predictive |
Cohort | 13 patients with prostate cancer were treated with Lycopene for this study. 10 controls were included. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.0002 |
Method Used | ELISA |
Clinical | Yes |
Remarks | Effect of Lycopene treatment on Biomarkers Connexin 43, bcl-2, bax, IGI-1, IGFPB3-3. First 3 markers were not statstically significant. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | IGF1 |